$CHI

BlackRock reports holding half of Calamos’ Series H preferreds. Calamos Convertible Opportunities & Income (NASDAQ: CHI) files a passive stake.

BlackRock reports owning 345,000 shares (50%) of Calamos Convertible Opportunities & Income Fund's (CHI) Series H preferred shares, with shared voting and dispositive power. Other institutions also hold significant stakes. The filing details ownership structure and compliance with SEC regulations.

Original reporting
Published Sep 8, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 6:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CHI
Neutral
high confidence
Mentioned
$CHI
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CHINeutralLow
01

Why it matters

The disclosure provides transparency on voting power and potential influence over fund decisions, useful for shareholders and analysts.

02

Market read

Primary disclosure of a large institutional stake in a listed fund, relevant for fund investors and analysts monitoring ownership concentration.

03

What to watch

Potential future changes to the fund's capital structure or redemption terms could affect share price.

Relevance 6/10Novelty 8/10Timing: filing date September 8, 2026

Background

Schedule 13G filings disclose passive ownership stakes exceeding 5% for institutional investors. This filing reveals BlackRock's 50% ownership of a specific class of preferred shares in CHI.

Company-level read

Ticker impact

$CHINeutralHigh confidence
Context

BlackRock Portfolio Management LLC disclosed beneficial ownership of 345,000 Series H preferred shares, representing 50% of the class, in a Schedule 13G filing.

Expected impact

Limited immediate price impact; potential for future influence on fund governance and capital structure.

Evidence & confidence

The filing is a primary disclosure of a substantial ownership position in a listed fund, which is material but does not directly alter cash flows.

Market effects

Highlights concentration of ownership in convertible fund preferred securities, relevant for investors tracking institutional holdings in the asset‑management sector.

U.S. market focus; no broader regional effect.

Limited to investors in the fund and its underlying holdings.

Counterpoint

The stake may signal BlackRock's confidence in the fund's preferred structure, but could also indicate a strategic move to influence future capital calls.

Key entities

  • BlackRock Portfolio Management LLC

    Beneficial owner of 345,000 Series H preferred shares of CHI.

  • Calamos Convertible Opportunities & Income Fund

    Issuer of Series H Mandatory Redeemable Preferred Shares (ticker CHI).

Related articles

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Launch Backlog Tops 100 After Synspective Deal

Rocket Lab's (RKLB) launch backlog exceeded 100 missions after a 20-launch deal with Synspective. The company's backlog grew from 70+ to over 100 missions in five months. Synspective is now Rocket Lab's largest customer with 47 launches. Rocket Lab's financial backlog was $2.2bn in Q1 2026, up 20.2% from the prior quarter. The company's revenue has doubled over two years, but it remains unprofitable.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.